Home/Pipeline/PRIME Study

PRIME Study

Quadriplegia (Cervical Spinal Cord Injury, ALS)

Phase 1Active

Key Facts

Indication
Quadriplegia (Cervical Spinal Cord Injury, ALS)
Phase
Phase 1
Status
Active
Company

About NeuralInk

Neuralink, founded in 2016, is a private medical device company at the forefront of brain-computer interface technology. Its core innovation is the N1 implant and the surgical robot used for precise implantation of ultra-thin electrode threads. The company's initial focus is on therapeutic applications for paralysis and blindness, with a first-in-human clinical trial underway. Backed by significant private investment and led by Elon Musk, Neuralink aims to translate its ambitious platform from medical restoration to broader human augmentation.

View full company profile

Therapeutic Areas